

iBody Inc. and Novalix Japan K.K. enter into business alliance: Strengthening integrated drug discovery services to accelerate antibody therapeutics development

iBody Inc. and Novalix Japan K.K. are pleased to announce that they have entered into a business alliance to strengthen support for clients engaged in antibody drug discovery and life science research.

Through this alliance, iBody's proprietary antibody discovery technology will be integrated within the Novalix Group's antibody evaluation technologies, while leveraging the Group's global business network, to establish a comprehensive support framework covering the acquisition and evaluation of candidate antibodies from the early stages of drug discovery research.

Background of the partnership

In recent years, the global market for antibody therapeutics has continued to expand, while the diversification and increasing complexity of drug targets have driven growing demand for the rapid acquisition and evaluation of highly functional antibodies.

iBody has developed a proprietary platform that enables the rapid and efficient acquisition of promising monoclonal antibodies from human- and rabbit-derived B cells. Leveraging this technology, the company provides antibody discovery support services to pharmaceutical companies and academic institutions.

Meanwhile, Novalix delivers advanced research support services in structural biology, biophysics, and other scientific disciplines for drug discovery research, including antibody drug discovery, on a global scale, supporting the research and development activities of numerous pharmaceutical and biotechnology companies.



Recognizing that the combination of their respective strengths would enable them to provide higher value-added drug discovery support solutions to researchers and pharmaceutical companies, the two companies have entered into this business alliance.

About iBody

iBody is a Nagoya University spin-off dedicated to the discovery and development of highly functional monoclonal antibodies to accelerate therapeutic and diagnostic development. Its platform combines proprietary single B-cell analysis technology with cell-free antibody expression technology, enabling the rapid acquisition of high-performance antibodies from human-, rabbit-, and alpaca-derived B cells. To date, iBody has successfully generated antibodies against challenging targets, including small molecules, single amino acid variants, and phosphorylated proteins, as well as cancer-specific antibodies and virus-neutralizing antibodies. Through contract research and collaborative research, iBody supports the research and development activities of pharmaceutical and diagnostic companies in Japan and overseas.

Head Office: Nagoya, Aichi, Japan

Representative: Yo (Max) Amakusa, Shoji Ohuchi

For more information about iBody's technologies and services, please visit <https://www.ibody.co.jp>

About Novalix

Novalix, headquartered in France, is a premier contract research organization (CRO), dedicated to improving the critical early stages of drug discovery by combining exceptional scientific talent and exclusive technology with a comprehensive portfolio of world-class chemistry, biophysics and pharmacology capabilities. We work collaboratively with our clients to meet the most complex scientific challenges, and our innovative partnerships with leading instrument makers and academic institutions help us continually expand the possibilities of human health.

Novalix Japan K.K. is the Japanese subsidiary of Novalix SAS, where Japanese staff provide clients with support for scientific discussions and contract negotiations.

Head Office: Minato-ku, Tokyo, Japan

Representative Director: Alain Decayeux

For more information about Novalix's technologies and services, please visit novalix.com